Table 5. Effect of renal function on clinical outcomes.
| Outcome | DOAC cohort and creatinine clearance a | |||||
|---|---|---|---|---|---|---|
| Apixaban | Dabigatran etexilate | Rivaroxaban | ||||
| 25–50 mL/min ( n = 234) | >50 mL/min ( n = 1023) | 30–50 mL/min ( n = 80) | >50 mL/min ( n = 588) | 30–50 mL/min ( n = 155) | >50 mL/min ( n = 927) | |
| Major bleeding | ||||||
| No. % (95% CI) | 1, 0.43 (0.08–2.4) | 16, 1.6 (0.96–2.5) | 1, 1.2 (0.22–6.7) | 5, 0.85 (0.36–2.0) | 5, 3.2 (1.4–7.3) | 15, 1.6 (0.98–2.6) |
| p -Value | p = 0.22 | p = 0.54 | p = 0.19 | |||
| Arterial thromboembolism | ||||||
| No. % (95% CI) | 1, 0.43 (0.08–2.4) | 1, 0.10 (0.02–0.55) | 0, 0.0 (0–4.6) | 4, 0.68 (0.26–1.7) | 1, 0.65 (0.11–3.6) | 3, 0.32 (0.11–0.95) |
| p -Value | p = 0.34 | p = 1.0 | p = 0.46 | |||
| Any bleed (MB + CRNMB) | ||||||
| No. % (95% CI) | 6, 2.6 (1.2–5.5) | 32, 3.1 (2.2–4.4) | 3, 3.7 (1.3–10.4) | 16, 2.7 (1.7–4.4) | 6, 3.9 (1.8–8.2) | 39, 4.2 (3.1–5.7) |
| p -Value | p = 0.83 | p = 0.49 | p = 1.0 | |||
| Any thromboembolism | ||||||
| No., % (95% CI) | 3, 1.3 (0.44–3.7) | 6, 0.59 (0.27–1.3) | 0, 0.0 (0–4.6) | 7, 1.2 (0.58–2.4) | 1, 0.65 (0.11–3.6) | 4, 0.43 (0.17–1.1) |
| p -Value | p = 0.38 | p = 1.0 | p = 0.54 | |||
Abbreviations: CI, confidence interval; CRNMB, clinically relevant nonmajor bleeding; DOAC, direct oral anticoagulant; MB, major bleeding.
a
Patients were excluded from the PAUSE study with CrCl <25 mL/min for apixaban, and <30 mL/min for dabigatran or rivaroxaban.
Note: Bold values represent the percentage of patients that experienced that clinical outcome.